Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Stereotaxis Inc (STXS)

Stereotaxis Inc (STXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 179,911
  • Shares Outstanding, K 97,249
  • Annual Sales, $ 32,380 K
  • Annual Income, $ -21,640 K
  • EBIT $ -22 M
  • EBITDA $ -21 M
  • 60-Month Beta 1.43
  • Price/Sales 5.53
  • Price/Cash Flow N/A
  • Price/Book 12.74

Options Overview Details

View History
  • Implied Volatility 109.35% (-8.91%)
  • Historical Volatility 44.39%
  • IV Percentile 48%
  • IV Rank 17.13%
  • IV High 404.93% on 03/09/26
  • IV Low 48.26% on 08/11/25
  • Expected Move (DTE 14) 0.7225 (38.64%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 90
  • Volume Avg (30-Day) 45
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 5,327
  • Open Int (30-Day) 5,355
  • Expected Range 1.1475 to 2.5925

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 2
  • High Estimate $-0.04
  • Low Estimate $-0.05
  • Prior Year $-0.07
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7400 +7.47%
on 03/19/26
2.3450 -20.26%
on 03/05/26
-0.3500 (-15.77%)
since 03/02/26
3-Month
1.7400 +7.47%
on 03/19/26
2.8600 -34.62%
on 01/15/26
-0.4500 (-19.40%)
since 01/02/26
52-Week
1.5400 +21.43%
on 04/07/25
3.5900 -47.91%
on 10/09/25
+0.1200 (+6.86%)
since 04/02/25

Most Recent Stories

More News
Stereotaxis Reports 2025 Full Year Financial Results

ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results...

STXS : 1.8700 (+1.08%)
Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026

ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will...

STXS : 1.8700 (+1.08%)
Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of...

STXS : 1.8700 (+1.08%)
Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S....

STXS : 1.8700 (+1.08%)
Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference

ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company...

STXS : 1.8700 (+1.08%)
Stereotaxis Reports 2025 Third Quarter Financial Results

ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results...

STXS : 1.8700 (+1.08%)
GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance

ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received...

STXS : 1.8700 (+1.08%)
Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025

ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will...

STXS : 1.8700 (+1.08%)
Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs

ST. LOUIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE...

STXS : 1.8700 (+1.08%)
Lake Street Reaffirms Their Buy Rating on Stereotaxis (STXS)

Lake Street analyst Frank Takkinen reiterated a Buy rating on Stereotaxis today and set a price target of $4.00. The company’s shares closed last Friday at $3.07.Elevate Your Investing Strategy: Take...

STXS : 1.8700 (+1.08%)

Business Summary

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to allow physicians to navigate catheters, guidewires...

See More

Key Turning Points

3rd Resistance Point 1.9783
2nd Resistance Point 1.9367
1st Resistance Point 1.9033
Last Price 1.8700
1st Support Level 1.8283
2nd Support Level 1.7867
3rd Support Level 1.7533

See More

52-Week High 3.5900
Fibonacci 61.8% 2.8069
Fibonacci 50% 2.5650
Fibonacci 38.2% 2.3231
Last Price 1.8700
52-Week Low 1.5400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.